Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00074412
First received: December 11, 2003
Last updated: July 5, 2013
Last verified: July 2013
Results First Received: May 30, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver);   Primary Purpose: Prevention
Condition: HIV Infections
Interventions: Drug: Nevirapine
Drug: Nevirapine placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
HIV-infected pregnant women were recruited from antenatal clinics at DAIDS Clinical Trials Sites in Zimbabwe, South Africa, Uganda & Tanzania between May 14, 2008 & January 20th 2010. 1700 mother/infant pairs were enrolled & infants were given daily doses of Nevirapine for 6 weeks at which point there were randomized to placebo or extended NVP.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Infants were excluded from randomization if in first 42 days: had a positive HIV-1 DNA PCR, breastfeeding was discontinued, never initiated or permanently discontinued open-label NVP, certain graded abnormal labs, skin rash grade2B or higher, clinical hepatitis, serious illness/condition that prevented compliance, or use of rifampin/ketoconazole.

Reporting Groups
  Description
Placebo For infants: extended treatment with NVP placebo
Nevirapine For infants: extended treatment with NVP

Participant Flow:   Overall Study
    Placebo     Nevirapine  
STARTED     763 [1]   759 [1]
Week 8 Visit     759     759  
Month 3 Visit     759     755  
Month 4 Visit     758     752  
Month 5 Visit     756     750  
Month 6 Visit     748     748  
Month 9 Visit     741     741  
Month 12 Visit     733     735  
COMPLETED     681 [2]   675 [2]
NOT COMPLETED     82     84  
Death                 30                 26  
Lost to Follow-up                 52                 58  
[1] Number of infants randomized at 6 weeks.
[2] Number of infants who completed final 18 month visit: out of 733 infants who were expected.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Nevirapine For infants: extended treatment with NVP
Placebo For infants: extended treatment with NVP placebo
Total Total of all reporting groups

Baseline Measures
    Nevirapine     Placebo     Total  
Number of Participants  
[units: participants]
  759     763     1522  
Age  
[units: participants]
     
<=18 years     759     763     1522  
Between 18 and 65 years     0     0     0  
>=65 years     0     0     0  
Gender, Customized  
[units: participants]
     
Ambiguous     1     0     1  
Male     363     398     761  
Female     395     365     760  
Region of Enrollment  
[units: participants]
     
Tanzania     98     99     197  
Uganda     259     261     520  
South Africa     171     171     342  
Zimbabwe     231     232     463  
Categorical Infant Birthweight (g)  
[units: participants]
     
Missing     0     1     1  
2000-2499     50     52     102  
2500-2999     214     211     425  
3000-3499     329     336     665  
>=3500     166     163     329  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study   [ Time Frame: At Month 6 ]

2.  Primary:   Frequency and Severity of Adverse Reactions Among Participating Infants   [ Time Frame: 6 weeks through 18 months ]

3.  Secondary:   Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms   [ Time Frame: At Months 6 and 18 ]
  Hide Outcome Measure 3

Measure Type Secondary
Measure Title Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Measure Description No text entered.
Time Frame At Months 6 and 18  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
There were 1522 infants randomized at 6 weeks of birth to either the extended Nevirapine arm (759) or the placebo arm (763).

Reporting Groups
  Description
Nevirapine For infants: extended treatment with NVP
Placebo For infants: extended treatment with NVP placebo

Measured Values
    Nevirapine     Placebo  
Number of Participants Analyzed  
[units: participants]
  759     763  
Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms  
[units: participants]
   
Number of Infants Alive and HIV-free at 6 months     689     683  
Number of Infants Alive and HIV-free at 18 months     629     616  


Statistical Analysis 1 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] Nevirapine
Method [2] Kaplan-Meier Method
Cum. Rate of HIV-free Survival 6mon (%) [3] 97.7
95% Confidence Interval ( 96.6 to 98.8 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rate of HIV-free survival at 6 months in the extended NVP arm was calculated using the Kaplan-Meier method; while the 95% CI was calculated using Greenwood's formula.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Other relevant estimation information:
  No text entered.

Statistical Analysis 2 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] Placebo
Method [2] Kaplan-Meier Method
Cum. Rate of HIV-free Survival 6mon (%) [3] 96.8
95% Confidence Interval ( 95.5 to 98.0 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rate of HIV-free survival at 6 months in the placebo arm was calculated using the Kaplan-Meier method; while the 95% CI was calculated using Greenwood's formula.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Other relevant estimation information:
  No text entered.

Statistical Analysis 3 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] All groups
Method [2] Z-test
P Value [3] 0.274
Z statistic [4] 1.095
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rates of HIV-free survival at 6 months were compared between the two groups using a Z-statistic.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value was not adjusted for interim analysis or multiple testing.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 4 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] Nevirapine
Method [2] Kaplan-Meier Method
Cum. Rate of HIV-free Survival 18mon (%) [3] 94.5
95% Confidence Interval ( 92.9 to 96.2 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rate of HIV-free survival at 18 months in the extended NVP arm was calculated using the Kaplan-Meier method; while 95% confidence intervals were calculated using Greenwood's formula.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Other relevant estimation information:
  No text entered.

Statistical Analysis 5 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] Placebo
Method [2] Kaplan-Meier Method
Cum. Rate of HIV-free Survival 18mon (%) [3] 93.3
95% Confidence Interval ( 91.5 to 95.1 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rate of HIV-free survival at 18 months in the placebo arm was calculated using the Kaplan-Meier method; while the 95% confidence interval was calculated using Greenwood's formula.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Other relevant estimation information:
  No text entered.

Statistical Analysis 6 for Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
Groups [1] All groups
Method [2] Z-test
P Value [3] 0.323
Z statistic [4] 0.988
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The cumulative rates of HIV-free survival at 18 months were compared between the two groups using a Z statistic.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value was not adjusted for interim analysis or multiple testing.
[4] Other relevant estimation information:
  No text entered.



4.  Secondary:   Relative Rates of HIV Infection in the Two Arms   [ Time Frame: At Month 18 ]

5.  Secondary:   Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms   [ Time Frame: At Month 18 ]

6.  Secondary:   Frequency and Duration of Maternal Plasma and Breast Milk NVP-resistant HIV Strains and the Relationship With HIV Transmission   [ Time Frame: Throughout study ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Relationship Between Maternal Plasma and Breast Milk RNA Levels and the Risk of MTCT   [ Time Frame: Throughout study ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

8.  Secondary:   Frequency and Duration of NVP-resistant HIV Strains in Plasma of HIV-infected Infants   [ Time Frame: Throughout study ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

9.  Secondary:   Rates of Disease Progression as Defined by CD4 Counts, HIV-1 RNA PCR, and Mortality in Infected Infants in the Two Arms   [ Time Frame: Throughout study ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

10.  Secondary:   NVP Concentrations in Infants Determined to be HIV-infected and in a Sample of HIV-uninfected Infants   [ Time Frame: Week 8 and Month 3 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The rate of maternal highly active antiretroviral therapy use was higher than expected in our study. Thus there were fewer infant infections which decreased the power to detect differences in HIV transmission risks between study groups.


  More Information